Brii Bioscience Ltd (BRIBF) Q2 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by and welcome to BRIE Biosciences Limited 2021 Interim Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session and instructions will follow at that time. It is now my pleasure to turn the call over to Ms. Chris Fang, Director of Investor Relations. Please go ahead, Chris. Thank you, operator. Welcome to BreVal 2021 Interim Financial Results and Business Update Conference Call. Our interim results announcement can be found on the Investor Relations section of our company website. Joining me today on the call from CompanySide Senior Management Team are Dr. Z. Hong, our co-founder, chairman, and chief executive officer Dr. Li Yan, who is our chief medical officer, and Dr. An Kang Li, our chief financial officer. Dr. Hong will provide us a high-level overview of our company strategy, market, and future development plan, and Dr. Yan will walk us through some of the key programs on the development, including our infectious disease and central nervous system programs. Dr. Li will then provide a brief summary of the financial results of the six months ending June 30, 2021, before we turn the call back over to the operator to take your questions. During the Q&A session, our Executive Director, President, and General Manager of Great China, Mr. Rogers Law, and our Senior VP, Dr. Zhu Qing, and VP, Head of Infectious Disease David Magones will join us to share more details. Before we start, we would like to remind you that today's discussion may contain forward-looking statements, which involve a number of risks and uncertainties. Actual results and outcomes may differ materially from those mentioned in today's announcement a...